CCI-779 |
TORISEL |
TEMSIROLIMUS |
CCI 779 |
TORISEL® |
42-[3-HYDROXY-2-(HYDROXYMETHYL)-2-METHYLPROPANOATE]RAPAMYCIN |
drugbank:06287 |
pubchem.compound:6918289 |
rxcui:657797 |
chembl:CHEMBL1201182 |
chemidplus:162635-04-3 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Pharmaceutical Developer | Wyeth Pharmaceuticals |
Source Reported Drug Name(s) | Temsirolimus |
Drug Class | mTOR Inhibitor |
Notes | rapalogue |
Drug Class | Kinase Inhibitors |
FDA Approval | Renal cell carcinoma |
Year of Approval | 2007 |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Drug Categories | antineoplastic agents |
Drug Categories | agents causing angioedema |
Drug Categories | anti-bacterial agents |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 inhibitors |
Drug Categories | cytochrome p-450 cyp3a5 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a5 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 cyp3a7 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | kinase inhibitor |
Drug Categories | mtor inhibitors |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
Drug Categories | sirolimus and prodrugs |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Mechanism of Interaction | FK506-binding protein 1A inhibitor |
Direct Interaction | yes |
n/a |
combination therapy | SCH772984 + Temsirolimus |
Indication/Tumor Type | pancreatic ductal adenocarcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
combination therapy | Bevacizumab + Temsirolimus + Doxil |
Indication/Tumor Type | ovarian carcinoma |
Response Type | sensitive |
TEMSIROLIMUS | DrugBank Drug Name |
162635-04-3 | CAS Number |
Gd-temsirolimus | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | agents causing angioedema |
TEMSIROLIMUS | Primary Drug Name |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Year of Approval | 2007 |
Temsirolimus | PubChem Drug Name |
6918289 | PubChem Drug ID |
Torisel | Drug Trade Name |
Drug Class | mTOR Inhibitor |
Source Reported Drug Name(s) | Temsirolimus |
Pharmaceutical Developer | Wyeth Pharmaceuticals |
CCI-779 | Development Name |
TEMSIROLIMUS | Generic Name |
TORISEL | Trade Name |
FDA Approval | Renal cell carcinoma |
Drug Class | Kinase Inhibitors |
Notes | rapalogue |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
D0ES1Q | TTD Drug ID |
TEMSIROLIMUS | Primary Drug Name |
TEMSIROLIMUS | Drug Generic Name |
TORISEL | Drug Trade Name |
TEMSIROLIMUS | GuideToPharmacology Ligand Name |